taxifolin ruthenium-p-cymene complex

The **taxifolin ruthenium-p-cymene complex** is a synthetic organometallic compound formed by coordinating taxifolin, a flavonoid, with ruthenium-p-cymene in a 2:1 ratio, exhibiting potent anticancer activity primarily against lung carcinoma. It inhibits cancer cell viability, stemness, epithelial-mesenchymal transition (EMT), migration, colony formation, and sphere formation in NSCLC cell lines (A549, NCI-H460) via downregulation of stem cell markers **SOX2** and **OCT4**, and modulation of the **PI3K/Akt/mTOR/EGFR** pathway, leading to cell cycle arrest, caspase-3-mediated apoptosis, and reduced β-catenin expression. In vivo, it restores lung histology in benzo[α]pyrene-induced models at doses of 50-200 mg/kg, upregulating p53 and caspase-3 while suppressing Akt, mTOR, and β-catenin; it also shows activity in breast and colon cancer models through AhR signaling and suppresses metastasis/angiogenesis via VEGF/β-catenin inhibition when formulated as PLGA nanoparticles (TaxRu-NPs).[1][3][4][7][8][10]

Other names

TaxRu